Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154)

C. Santoro, M. Cappa, C. Moretti, A. Fabbri, V. La Vecchia, L. Romano Marcellino, F. Fraioli

Research output: Contribution to journalArticle

Abstract

A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75% of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.

Original languageEnglish
Pages (from-to)479-481
Number of pages3
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume20
Issue number10
Publication statusPublished - 1982

Fingerprint

Fibrocystic Breast Disease
Bromocriptine
Xerography
Mammography
Xeroradiography
Gonadotropins
Progesterone
Estradiol
Therapeutics
Recovery
ergocryptine
Serum

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Santoro, C., Cappa, M., Moretti, C., Fabbri, A., La Vecchia, V., Romano Marcellino, L., & Fraioli, F. (1982). Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154). International Journal of Clinical Pharmacology Therapy and Toxicology, 20(10), 479-481.

Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154). / Santoro, C.; Cappa, M.; Moretti, C.; Fabbri, A.; La Vecchia, V.; Romano Marcellino, L.; Fraioli, F.

In: International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 20, No. 10, 1982, p. 479-481.

Research output: Contribution to journalArticle

Santoro, C, Cappa, M, Moretti, C, Fabbri, A, La Vecchia, V, Romano Marcellino, L & Fraioli, F 1982, 'Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154)', International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 20, no. 10, pp. 479-481.
Santoro, C. ; Cappa, M. ; Moretti, C. ; Fabbri, A. ; La Vecchia, V. ; Romano Marcellino, L. ; Fraioli, F. / Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154). In: International Journal of Clinical Pharmacology Therapy and Toxicology. 1982 ; Vol. 20, No. 10. pp. 479-481.
@article{85f0ad43d2de48fc91be2bdba34cbc6b,
title = "Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154)",
abstract = "A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75{\%} of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.",
author = "C. Santoro and M. Cappa and C. Moretti and A. Fabbri and {La Vecchia}, V. and {Romano Marcellino}, L. and F. Fraioli",
year = "1982",
language = "English",
volume = "20",
pages = "479--481",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0174-4879",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "10",

}

TY - JOUR

T1 - Treatment of benign fibrocystic disease of the breast with 2-bromo-α-ergocryptine (CB 154)

AU - Santoro, C.

AU - Cappa, M.

AU - Moretti, C.

AU - Fabbri, A.

AU - La Vecchia, V.

AU - Romano Marcellino, L.

AU - Fraioli, F.

PY - 1982

Y1 - 1982

N2 - A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75% of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.

AB - A total of 192 patients with benign fibrocystic disease of the breast were studied. Diagnosis was based on the clinical picture, xerography, and/or mammography. Most of the patients were 30-45 years old. Hormonal studies including serum PRL, 17-β-estradiol, progesterone, and gonadotropins were performed by means of specific and sensitive RIA techniques. Patients were allotted to treatment with 3 x 2.5 mg p.o. 2-bromo-α-ergocryptine (CB 154, Parlodel, Sandoz) continuously for a period of 3 months. In an attempt to establish a possible relationship between PRL levels and the disease, patients were divided into two groups with high or normal levels of PRL. Results indicate an improvement or complete recovery in about 75% of the cases. These results are independent of PRL levels. According to the authors' experience CB 154 seems to be the most effective treatment of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0019981741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019981741&partnerID=8YFLogxK

M3 - Article

C2 - 6815107

AN - SCOPUS:0019981741

VL - 20

SP - 479

EP - 481

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0174-4879

IS - 10

ER -